Literature DB >> 27174526

Edaravone Reduces Hyperperfusion-Related Neurological Deficits in Adult Moyamoya Disease: Historical Control Study.

Haruto Uchino1, Naoki Nakayama2, Ken Kazumata2, Satoshi Kuroda2, Kiyohiro Houkin2.   

Abstract

BACKGROUND AND
PURPOSE: Postoperative hyperperfusion-related transient neurological deficits (TNDs) are frequently observed in adult patients with moyamoya disease who undergo direct bypass procedures. The present study evaluated the effect of the free radical scavenger edaravone on postoperative hyperperfusion in adult moyamoya disease.
METHODS: This study included 92 hemispheres in 72 adult patients who underwent direct bypass for moyamoya disease. Serial measurements of cerebral blood flow were conducted immediately after surgery and on postoperative days 2 and 7. In 40 hemispheres for 36 patients, edaravone (60 mg/d) was administered from the day of surgery to postsurgical day 7. The incidence of postoperative hyperperfusion and associated TNDs were compared with a control group that included 52 hemispheres in 36 patients.
RESULTS: Radiological hyperperfusion was observed in 28 of 40 (70.0%) and 39 of 52 (75.0%) hemispheres in the edaravone and control groups, respectively (P=0.30). Hyperperfusion-related TND incidences were significantly lower in the edaravone group compared with the control group (12.5% versus 32.7%; P=0.024). Multivariate analysis demonstrated that edaravone administration (P=0.009) and left-sided surgery (P=0.037) were significantly correlated with hyperperfusion-related TNDs (odds ratios, 0.3 and 4.2, respectively).
CONCLUSIONS: Perioperative administration of edaravone reduced the incidence of hyperperfusion-related TNDs after direct bypass procedures in adult patients with moyamoya disease.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  STA-MCA bypass; free radical scavengers; moyamoya disease; neurologic deficits; phenylmethylpyrazolone; reperfusion

Mesh:

Substances:

Year:  2016        PMID: 27174526     DOI: 10.1161/STROKEAHA.116.013304

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Efficacy of superficial temporal artery-middle cerebral artery double bypass in patients with hemorrhagic moyamoya disease: surgical effects for operated hemispheric sides.

Authors:  Taichi Ishiguro; Yoshikazu Okada; Tatsuya Ishikawa; Koji Yamaguchi; Akitsugu Kawashima; Takakazu Kawamata
Journal:  Neurosurg Rev       Date:  2018-12-03       Impact factor: 3.042

2.  Crossed cerebellar diaschisis as an indicator of severe cerebral hyperperfusion after direct bypass for moyamoya disease.

Authors:  Haruto Uchino; Ken Kazumata; Masaki Ito; Naoki Nakayama; Satoshi Kuroda; Kiyohiro Houkin
Journal:  Neurosurg Rev       Date:  2020-02-19       Impact factor: 3.042

3.  Postoperative stroke and neurological outcomes in the early phase after revascularization surgeries for moyamoya disease: an age-stratified comparative analysis.

Authors:  Yoshio Araki; Kinya Yokoyama; Kenji Uda; Fumiaki Kanamori; Michihiro Kurimoto; Yoshiki Shiba; Takashi Mamiya; Masahiro Nishihori; Takashi Izumi; Masaki Sumitomo; Sho Okamoto; Kota Matsui; Ryo Emoto; Toshihiko Wakabayashi; Shigeyuki Matsui; Atsushi Natsume
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

4.  Progressive Cortical Neuronal Damage and Extracranial-Intracranial Bypass Surgery in Patients with Misery Perfusion.

Authors:  H Yamauchi; S Kagawa; Y Kishibe; M Takahashi; T Higashi
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-02       Impact factor: 3.825

5.  Pre-operative higher hematocrit and lower total protein levels are independent risk factors for cerebral hyperperfusion syndrome after superficial temporal artery-middle cerebral artery anastomosis with pial synangiosis in adult moyamoya disease patients-case-control study.

Authors:  Masahito Katsuki; Miki Fujimura; Ryosuke Tashiro; Yasutake Tomata; Taketo Nishizawa; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2020-09-24       Impact factor: 3.042

6.  2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society.

Authors:  Miki Fujimura; Teiji Tominaga; Satoshi Kuroda; Jun C Takahashi; Hidenori Endo; Kuniaki Ogasawara; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

7.  Multimodal neuronavigation-guided precision bypass in adult ischaemic patients with moyamoya disease: study protocol for a randomised controlled trial.

Authors:  Junlin Lu; Yahui Zhao; Li Ma; Yu Chen; Mingtao Li; Xun Ye; Rong Wang; Xiaolin Chen; Yuanli Zhao
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

8.  Long-Lasting Symptomatic Cerebral Hyperperfusion Syndrome following Superficial Temporal Artery-Middle Cerebral Artery Bypass in a Patient with Stenosis of Middle Cerebral Artery.

Authors:  Shinji Shimato; Toshihisa Nishizawa; Takashi Yamanouchi; Takashi Mamiya; Kojiro Ishikawa; Kyozo Kato
Journal:  Case Rep Neurol Med       Date:  2018-09-23

Review 9.  Severe cerebral edema induced by watershed shift after bypass in a patient with chronic steno-occlusive disease: a case report and short literature review.

Authors:  Yin Li; Yu-Yu Wei; Yang Cao; Xiao-Yang Lu; Yuan Yao; Lin Wang
Journal:  BMC Neurol       Date:  2020-09-05       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.